(Q38128548)

29 August 2017

title

Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

29 August 2017

0 references

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

1 reference

J K Dyson

1

1 reference

29 August 2017

S McPherson

series ordinal

2

1 reference

29 August 2017

Q M Anstee

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

12 August 2013

1 reference

Journal of Clinical Pathology

29 August 2017

published in

1 reference

29 August 2017

volume

66

1 reference

29 August 2017

issue

12

1 reference

29 August 2017

page(s)

1033-1045

1 reference

Epidemiology and natural history of non-alcoholic steatohepatitis

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

The epidemiology of fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Liver fat in the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Genetic modifiers of non-alcoholic fatty liver disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Cholesterol and nonalcoholic fatty liver disease: renewed focus on an old villain

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Chronic liver injury during obstructive sleep apnea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Effects of obstructive sleep apnea syndrome on hepatic steatosis and nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Steatosis is a cofactor in liver injury in hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Investigating mildly abnormal serum aminotransferase values

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

EASL clinical practice guidelines for HFE hemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

A simple index of lipid overaccumulation is a good marker of liver steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Role of radiologic modalities in the management of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Noninvasive liver steatosis quantification using MRI techniques combined with blood markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Apoptosis and necrosis in the liver: a tale of two deaths?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Problems with NASH? HAIR is some help

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

A "biomarker biopsy" for the diagnosis of NASH: promises from CK-18 fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

An apoptosis panel for nonalcoholic steatohepatitis diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Review article: role of oxidative stress in the progression of non-alcoholic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Liver fibrosis in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Comparison of blood tests for liver fibrosis specific or not to NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Serum markers detect the presence of liver fibrosis: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

The utility of the "NAFLD fibrosis score" in morbidly obese subjects with NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Mortality in nonalcoholic fatty liver disease: clues from the Cremona study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Meta-analyses of FibroTest diagnostic value in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

A parallel tracking method for acoustic radiation force impulse imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

A Germline DNA Polymorphism Enhances Alternative Splicing of theKLF6Tumor Suppressor Gene and Is Associated with Increased Prostate Cancer Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

Nonalcoholic Fatty Liver Disease in Severely Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FJCLINPATH-2013-201620

10.1136/JCLINPATH-2013-201620

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference